|Day Low/High||0.00 / 0.01|
|52 Wk Low/High||0.00 / 0.01|
NeurogesX's CEO Discusses Q2 2012 Results - Earnings Call Transcript
The top 10 open-market insider purchases and sales filed at the SEC Monday.
These health care stocks are scheduled to report their quarterly earnings today.
The following 10 biotech stocks, though exceptionally risky, are expected to double, triple or quadruple in the next 12 months.
Kodiak Oil & Gas announces the pricing of its public offering of 25 million shares.
A single one-hour Qutenza localized treatment can provide three months relief from pain associated with postherpetic neuralgia
Scheduled to Ring NASDAQ Opening Bell on April 6, 2010
Earnings roundup: Palm's phone sales slump, Cintas profit slides as unemployment rose
NeurogesX shares rise as Food and Drug Administration approves Qutenza pain patch
NeurogesX receives Food and Drug Administration approval for Qutenza pain patch
Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.
NeurogesX said it named Bradford Goodwin to board, regaining compliance with Nasdaq rules
NeurogesX to perform small, add-on study of Qutenza following agreement with FDA
It's not clear how this tiny biotech's pain patch can compete with a host of rivals, large and small.
A study shows that its NGX-4010 reduced pain for eight weeks in patients with postherpetic neuralgia.